On November 20, 2023, Sonoma Pharmaceuticals Inc. (NASDAQ: SNOA) opened at $0.16, higher 20.26% from the last session. During the day, the shares moved up to $0.192 and dropped to $0.16 before settling in for the closing price of $0.16. Price fluctuations for SNOA have ranged from $0.12 to $2.68 over the past 52 weeks.
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -2.96%. Company’s average yearly earnings per share was noted 29.49% at the time writing. With a float of $13.08 million, this company’s outstanding shares have now reached $13.68 million.
Considering the fact that the conglomerate employs 171 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is +33.73, operating margin of -34.43, and the pretax margin is -39.06.
Sonoma Pharmaceuticals Inc. (SNOA) Insider Activity
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Sonoma Pharmaceuticals Inc. is 4.39%, while institutional ownership is 1.03%.
Sonoma Pharmaceuticals Inc. (SNOA) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 9/29/2023, the company posted -$0.29 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -$0.24) by -$0.05. This company achieved a net margin of -38.81 while generating a return on equity of -61.78. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 29.49% per share during the next fiscal year.
Sonoma Pharmaceuticals Inc. (NASDAQ: SNOA) Trading Performance Indicators
Check out the current performance indicators for Sonoma Pharmaceuticals Inc. (SNOA). In the past quarter, the stock posted a quick ratio of 2.70. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.22.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.48, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.36 in one year’s time.
Technical Analysis of Sonoma Pharmaceuticals Inc. (SNOA)
Compared to the last year’s volume of 0.77 million, its volume of 0.22 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 75.61%. Additionally, its Average True Range was 0.04.
During the past 100 days, Sonoma Pharmaceuticals Inc.’s (SNOA) raw stochastic average was set at 7.06%, which indicates a significant decrease from 99.61% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 132.00% in the past 14 days, which was lower than the 141.76% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5460, while its 200-day Moving Average is $0.9422. Nevertheless, the first resistance level for the watch stands at $0.2025 in the near term. At $0.2132, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.2345. If the price goes on to break the first support level at $0.1705, it is likely to go to the next support level at $0.1492. Should the price break the second support level, the third support level stands at $0.1385.
Sonoma Pharmaceuticals Inc. (NASDAQ: SNOA) Key Stats
There are currently 13,679K shares outstanding in the company with a market cap of 2.62 million. Presently, the company’s annual sales total 13,270 K according to its annual income of -5,150 K. Last quarter, the company’s sales amounted to 3,430 K and its income totaled -1,420 K.